BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34063139)

  • 1. A Validated LC-MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation.
    Attwa MW; Darwish HW; Al-Shakliah NS; Kadi AA
    Molecules; 2021 May; 26(9):. PubMed ID: 34063139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma-Application to a Pharmacokinetic Study.
    Hefnawy MM; Alanazi MM; Al-Hossaini AM; Alnasser AI; El-Azab AS; Jardan YAB; Attwa MW; El-Gendy MA
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies.
    Attwa MW; Kadi AA; Abdelhameed AS; Alhazmi HA
    Drug Des Devel Ther; 2020; 14():783-793. PubMed ID: 32158196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of zorifertinib metabolic stability in human liver microsomes using LC-MS/MS.
    Attwa MW; Al-Shakliah NS; AlRabiah H; Kadi AA; Abdelhameed AS
    J Pharm Biomed Anal; 2022 Mar; 211():114626. PubMed ID: 35123331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes.
    Attwa MW; AlRabiah H; Kadi AA
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes.
    Mostafa GAE; Kadi AA; AlMasoud N; Attwa MW; Al-Shakliah NS; AlRabiah H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1179():122806. PubMed ID: 34325312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation.
    Attwa MW; Abdelhameed AS; Kadi AA
    Drug Des Devel Ther; 2021; 15():3915-3925. PubMed ID: 34552321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method.
    Attwa MW; AlRabiah H; Mostafa GAE; Bakheit AH; Kadi AA
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay.
    Attwa MW; Abdelhameed AS; Al-Shakliah NS; Kadi AA
    Drug Des Devel Ther; 2020; 14():4439-4449. PubMed ID: 33122888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an LC-MS/MS Method for Quantification of Sapitinib in Human Liver Microsomes: In Silico and In Vitro Metabolic Stability Evaluation.
    Attwa MW; AlRabiah H; Mostafa GAE; Kadi AA
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes.
    Attwa MW; Abdelhameed AS; Alsaif NA; Kadi AA; AlRabiah H
    RSC Adv; 2022 Jul; 12(31):20387-20394. PubMed ID: 35919584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encorafenib and Binimetinib: First Global Approvals.
    Shirley M
    Drugs; 2018 Aug; 78(12):1277-1284. PubMed ID: 30117021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Alectinib Metabolic Stability in HLMs Using Fast LC-MS/MS Method: In Silico ADME Profile, P450 Metabolic Lability, and Toxic Alerts Screening.
    Attwa MW; AlRabiah H; Mostafa GAE; Kadi AA
    Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation.
    Abdelhameed AS; Attwa MW; Kadi AA
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33126762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
    Rose AAN
    Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability.
    Abdelhameed AS; Kadi AA; Attwa MW; AlRabiah H
    PLoS One; 2019; 14(4):e0214598. PubMed ID: 30947315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance.
    Tang LWT; Chan ECY
    J Pharm Biomed Anal; 2022 May; 214():114731. PubMed ID: 35325798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid LC-MS/MS Bosutinib Quantification with Applications in Metabolic Stability Estimation.
    Attwa MW; Alanazi MM
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.